




ITW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 54704.8036.US03 (UMD-0072)  
Inventors: John Langenfeld  
Serial No.: 10/692,824  
Filing Date: October 23, 2003  
Examiner: Stephen L. Rawlings  
Customer No.: 46046  
Group Art Unit: 1642  
Confirmation No.: 1322  
Title: Bone Morphogenetic Protein-2 in the  
Treatment and Diagnosis of Cancer

I, Jane Massey Licata, Registration No. 32,257,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: September 22, 2005

  
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R.  
§§1.97-1.98, information relating to the above-identified  
application is hereby disclosed. Inclusion of information in  
this statement is not to be construed as an admission that this  
information is material as that term is defined in 37 C.F.R.  
§1.56(b).

- (XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is attached hereto; or
- ( ) Authorization to charge Deposit Account No. 50-1619 the fee of \$180.00 as set forth in §1.17(p) is provided.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,




Jane Massey Licata  
Registration No. 32,257

Date: September 22, 2005

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. 54704.8036.US03 (UMD-0072)	Serial No. 10/692,824
		Applicant John Langenfeld	
		Filing Date October 23, 2003	Group 1642
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BA	Alden et al., "In Vivo Endochondral Bone Formation Using a Bone Morphogenetic Protein 2 Adenoviral Vector", Human Gene Therapy 1999 10:2245-2253	
	BB	Benezra et al., "The Id proteins and angiogenesis", Oncogene 2001 20:8334-8341	
	BC	Bessho et al., "Bone induction by <i>Escherichia coli</i> -derived recombinant human bone morphogenetic protein-2 compared with Chinese hamster ovary cell-derived recombinant human bone morphogenetic protein-2", British Journal of Oral and Maxillofacial Surgery 2000 38:645-649	
	BD	Cameron et al., "Polyarginines Are Potent Furin Inhibitors", J. Biol. Chem. 2000 275(47):36741-36749	
	BE	Deckers et al., "Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A", Endocrinology 2002 143(4):1545-1553	
	BF	Gerber et al., "Angiogenesis and Bone Growth", Trends Cardiovasc Med 2000 10:223-228	
	BG	Goumans et al., "Balancing the activation state of endothelium via two distinct TGF- $\beta$ type I receptors", The EMBO Journal 2002 21(7):1743-1753	
	BH	Hay et al., "Bone Morphogenetic Protein-2 Promotes Osteoblast Apoptosis through a Smad-independent, Protein Kinase C-dependent Signaling Pathway", J. Biol. Chem. 2001 276(31):29028-29036	
	BI	Holmes et al., "Identification of Id2 as a Globin Regulatory Protein by Representational Difference Analysis of K562 Cells Induced To Express $\gamma$ -Globin with a Fungal Compound", Molecular and Cellular Biology 1999 19(6):4182-4190	
EXAMINER		DATE CONSIDERED	

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. 54704.8036.US03 (UMD-0072)	Serial No. 10/692,824
		Applicant <b>John Langenfeld</b>	
		Filing Date <b>October 23, 2003</b>	Group <b>1642</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BJ	Ide et al., "Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs", Oncogene 1997 14:1377-1382	
	BK	Izumi et al., "Bone Morphogenetic Protein-2 Inhibits Serum Deprivation-induced Apoptosis of Neonatal Cardiac Myocytes through Activation of the Smad1 Pathway", J. Biol. Chem. 2001 276(33):31133-31141	
	BL	Jin et al., "Overexpression of BMP-2/4,-5 and BMPR-IA associated with malignancy of oral epithelium", Oral Oncology 2001 37:225-233	
	BM	Kawamura et al., "Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3", Blood 2000 96(6):2005-2011	
	BN	King et al., "Bone morphogenetic protein-2 stimulates cell recruitment and cementogenesis during early wound healing", J. Clin Periodontol 2001 28(5):465-475	
	BO	Kirsch et al., "BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II", The EMBO Journal 2000 19(13):3314-3324	
	BP	Korchynskiy et al., "Identification and Functional Characterization of Distinct Critically Important Bone Morphogenetic Protein-specific Response Elements in the Id1 Promoter", J. Biol. Chem. 2002 277(7):4883-4891	
	BQ	Kretzschmar et al., "Opposing BMP and EGF signalling pathways converge on the TGF- $\beta$ family mediator Smad1", Nature 1997 389:618-622	
	BR	Lawson et al., "Bmp4 is required for the generation of primordial germ cells in the mouse embryo", Genes & Development 1999 13:424-436	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. 54704.8036.US03 (UMD-0072)	Serial No. 10/692,824
		Applicant <b>John Langenfeld</b>	
		Filing Date <b>October 23, 2003</b>	Group <b>1642</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BS	Lechleider et al., "Targeted Mutagenesis of <i>Smad1</i> Reveals an Essential Role in Chorioallantoic Fusion", <i>Developmental Biology</i> 2001 240:157-167	
	BT	Liu et al., "Human Type II Receptor for Bone Morphogenic Proteins (BMPs):Extension of the Two-Kinase Receptor Model to the BMPs", <i>Molecular and Cellular Biology</i> 1995 15(7):3479-3486	
	BU	Lyden et al., "Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts", <i>Nature</i> 1999 401:670-677	
	BV	Oro et al., "Basal Cell Carcinomas in Mice Overexpressing Sonic Hedgehog", <i>Science</i> 1997 276:817-821	
	BW	Reiriz et al., "BMP-2 and cAMP Elevation Confer Locus Coeruleus Neurons Responsiveness to Multiple Neurotrophic Factors", <i>J. Neurobiol</i> 2002 50:291-304	
	BX	Sloan et al., "Stimulation of the dentine-pulp complex of rat incisor teeth by transforming growth factor- $\beta$ isoforms 1-3 in vitro", <i>Archives of Oral Biology</i> 1999 44:149-156	
	BY	Tang et al., "The Helix-Loop-Helix Protein Id-1 Delays Onset of Replicative Senescence in Human Endothelial Cells", <i>Laboratory Investigation</i> 2002 82(8):1073-1079	
	BZ	Valdimarsdottir et al., "Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Protein-Induced Activation of Endothelial Cells", <i>Circulation</i> 2002 106:2263-2270	
	CA	Wu et al., "Utilization of Distinct Signaling Pathways by Receptors for Vascular Endothelial Cell Growth Factor and Other Mitogens in the Induction of Endothelial Cell Proliferation", <i>J. Biol. Chem.</i> 2000 275(7):5096-5103	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. 54704.8036.US03 (UMD-0072)	Serial No. 10/692,824
		Applicant <b>John Langenfeld</b>	
		Filing Date <b>October 23, 2003</b>	Group <b>1642</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	CB	Xiao et al., "Nucleocytoplasmic Shuttling of Smad1 Conferred by Its Nuclear Localization and Nuclear Export Signals", J. Biol. Chem. 2001 276(42):39404-39410	
	CC	Yang et al., "Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5", Development 1999 126:1571-1580	
	CD	Yeh et al., "Osteogenic protein-1 increases gene expression of vascular endothelial growth factor in primary cultures of fetal rat calvaria cells", Molecular and Cellular Endocrinology 1999 153:113-124	
	CE	Zetter et al., "Angiogenesis and Tumor Metastasis", Annu. Rev. Med. 1998 49:407-424	
EXAMINER		DATE CONSIDERED	